Streamex Corp. · NASDAQ:STEX
Streamex — BioSig Technologies — Investor Presentation (February 2021)
18 slides from Streamex's investor presentation, Feb 23, 2021
Slide 1: Corporate Presentation
: BioSic Pi technologies Corporate Presentation Winter 2024 NASDAQ : BSGM g
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by BioSig of new pr
Slide 3: Who We Are - NASDAQ: BSGM
Who We Are - NASDAQ: BSGM Er SEE MORE, CLEARLY EP Tech Market 13.5% CAGR Global EP Market Expected to be $12.2 Billion by 2026* 31 Patents Issued First Customer is #1 Center by Volume in U.S. Razor & Blade Business Model FDA Approved Unblinding of clinical data in 2021 BiOS igh: <1, meceansen Gorm e
Slide 4: PURE EP™ Developed Through Collaboration with Leading Centers
PURE EP™ Developed Through Collaboration with Leading Centers Relationships at leading, high-volume centers create traction for PURE EP™ in the market 2011 2013 2014 2014 2015 2016 Concept developed Proof of concept Prototypetest Initial pre-clinical First pre-clinical Advanced research with Texas C
Slide 5: Market Opportunity - PURE EP™
Market Opportunity - PURE EP ™ Complex Cardiac Ablation: 13.5% Growth Rate 3,425 EP labs Total Global Addressable Market $2.0 Billion SYMBOL: BSGM 5
Slide 6: EP During COVID-19
EP During COVID-19 + Delaying procedure increases stroke risk and worsens outcomes + From 2019 to 2020 ablations and LAAO (DRG 274) had a reimbursement rate increase of 8.8% + CV surgery and invasive cardiology have the highest net annual revenue compared to all other service lines CMS Reimbursement
Slide 7: PURE EP™ ASU - Customer Insights
PURE EP™ ASU = Customer InseVENors Hospital of the zs if aD University of Pennsylvania a 4 \ 4 \ im PUREEP™ Texas Cardiac Arrhythmia Institute SYMBOL: BSGM 7
Slide 8: Challenges in EP For All Procedures
Challenges in EP For All Procedures ae ‘Eh fj Signal Quality Success Rate Physicians Can’t Fix What They Can’t See 81% of physicians rated 20 - 40% of ablations are signal quality as “Critical” unsuccessful PURE EP SYMBOL: BSGM
Slide 9: Expanded Product Adoption, Experience, and a Growing Database
Expanded Product Adoption, Experience, and a Growing Database # PURE EP Procedures by Account # Physician Users 266 103 70 Diagnosis Diagnosis Persistent AF Atypical Flutter Overland Park (KS) Paroxysmal AF 1 Atrial Tachycardia Memorial (IN) Memorial Eve IEE 1 cases (4 ctrs) Other EE Ctrs Ischemic V
Slide 10: Our Clinical Path
Our Clinical Path EP" PRE-CLINICAL STUDIES +23 studies + Mayo Clinic, Mount Sinai, University of Pennsylvania + Published peer reviews in leading journals BioSig’ technologes' FIRST-IN-HUMAN CASES: +21 patients *TCAl, Greenvill Memorial Hospital, University of Indiana + Result improved signal fideli
Slide 11: Clinical Data PURE EP™ 2.0 Studies
Clinical Data PURE EP™ 2.0 Studies ¢ The Primary Aim: to further establish the safety and effectiveness of the PURE EP™ System. ¢ The Secondary Aim: to assess the quality and clinical relevance of the PURE EP™ System’s signals when compared to other sources of intracardiac signals. Stage 1: COMPLETE
Slide 12: Physician Testimonies
Physician Testimonies “The PURE EP System does provide innovative design with greater resolution and greater bandwidth, which should allow for safer and more efficacious ablations in the future.” - K. Venkatachalam, M.D., Cardiac Electrophysiologist, Mayo Clinic “The quality of the recording that we
Slide 13: Commercialization - Regions and Centers of Excellence
Commercialization - Regions and Centers of Excellence ore Revenue Potential $286 Million Florida 120 EP Programs 240 Labs Texas 220 EP Programs 440 Labs Northeast 175 EP Programs 400 Labs SYMBOL: BSGM 13
Slide 14: Business Model
Business Model PURE El" SEE MORE, CLEARLY Offers software solutions for clinically validated applications + Additional revenue from training, installation, and software upgrades * Foundation of the business model starts withthe PUREEP™System + Revenue from buying, leasing, and renting the product Bi
Slide 15: Unique Collaboration with Mayo Clinic
Unique Collaboration with Mayo Clinic || + 10-yearstrategicagreement i Joint IP filin, fi Licensing op) ortunities. r + First PURE EP™ System installed at BioSig Collaboration on technology development {+ ae MA Mayo cine as invested capital in the development of the PURE EP! stem. CLI NIC New R&D pr
Slide 16: Strong IP Portfolio
Strong IP Portfolio 31 allowed/issued worldwide design and utility patents, which cover various features of the PURE EP™ System’s display screens and graphical user interface for enhanced visualization of biomedical signals Differentiated combination of hardware and software is supported by strong I
Slide 17: Value Drivers
Value Drivers * Raised $41 million in 2020 * $32 million in cash on the balance sheet and no debt ¢ Achieved first commercial contract 4Q20 ¢ Expect to triple the customer base in 2021 ¢ Expect sequential revenue growth in 2021 ¢ Expect CE mark approval / EU entry 2022 jy Nasdaq: BSGM BioSig SYMBOL:
Slide 18: Management Team
Management Team Natasha Drapeau Steve Chaussy, CPA Execitive ice Present oro Neuroclear Technolgies Allance or esc Institute of irecters UK: 6 Group Fi, Barry Keenan, Ph.D, MBA, PMP Todd Wiltshire Senior Viee President, corporate Development Fidelitylovestmert red agicale, UBS; Morgan stariey ranney
BioSig Technologies — Investor Presentation (February 2021) on 6ix